论文部分内容阅读
目的观察双黄连注射液治疗恶性血液病并肺部感染的临床疗效及安全性。方法选择2006年4月～2008年4月我院住院恶性血液病合并肺部感染患者100例,随机分为治疗组50例和对照组50例,对照组单用第三代头孢茵素2g(头孢曲松等);治疗组在对照组基础上加用双黄连注射液60mg/kg,静脉滴注,每日一次,5天～7天一疗程。结果治疗组总有效率96%。对照组总有效率76%,两组比较有显著差异(p<0.01),两组症状改善时间有显著差异(p<0.01),未发现明显毒副作用。结论双黄连治疗恶性血液病并肺部感染具有抗感染、退热快、起效快等作用。
Objective To observe the clinical efficacy and safety of Shuanghuanglian injection in the treatment of hematologic malignancies and pulmonary infections. Methods From April 2006 to April 2008, 100 hospitalized patients with malignant hemorrhagic disease and pulmonary infection in our hospital were randomly divided into treatment group (50 cases) and control group (50 cases). The control group was treated with the third generation cephalosporin 2g Ceftriaxone, etc.); treatment group in the control group plus shuanghuanglian injection 60mg / kg, intravenous infusion, once daily, 5 days to 7 days a course of treatment. Results The total effective rate of the treatment group was 96%. The total effective rate of the control group was 76%, there was significant difference between the two groups (p <0.01). There was significant difference between the two groups (p <0.01). No obvious side effects were found. Conclusion Shuanghuanglian treatment of hematological malignancies and lung infection with anti-infection, fever, rapid onset and so on.